Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ENLV logo ENLV
Upturn stock ratingUpturn stock rating
ENLV logo

Enlivex Therapeutics Ltd (ENLV)

Upturn stock ratingUpturn stock rating
$1.06
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

09/15/2025: ENLV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10

1 Year Target Price $10

Analysts Price Target For last 52 week
$10 Target price
52w Low $0.81
Current$1.06
52w High $2.1

Analysis of Past Performance

Type Stock
Historic Profit -56.61%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 09/15/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 25.53M USD
Price to earnings Ratio -
1Y Target Price 10
Price to earnings Ratio -
1Y Target Price 10
Volume (30-day avg) 2
Beta 0.83
52 Weeks Range 0.81 - 2.10
Updated Date 09/15/2025
52 Weeks Range 0.81 - 2.10
Updated Date 09/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.57

Earnings Date

Report Date 2025-08-18
When -
Estimate -0.1527
Actual -0.1127

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -34.82%
Return on Equity (TTM) -55.02%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 6501382
Price to Sales(TTM) -
Enterprise Value 6501382
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.49
Shares Outstanding 23858300
Shares Floating 21346022
Shares Outstanding 23858300
Shares Floating 21346022
Percent Insiders 4.61
Percent Institutions 10.91

ai summary icon Upturn AI SWOT

Enlivex Therapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company developing Allocetra, an off-the-shelf cell therapy designed to reprogram immune cells in life-threatening conditions. Founded in 2005, it focuses on harnessing the body's natural mechanisms for homeostasis.

business area logo Core Business Areas

  • Immunotherapy Development: Develops and commercializes Allocetra for treating conditions like sepsis and cytokine storm associated with COVID-19 and other diseases.

leadership logo Leadership and Structure

Dr. Oren Hershkovitz serves as CEO. The company has a board of directors and operates with departments dedicated to research, development, clinical trials, and business development.

Top Products and Market Share

overview logo Key Offerings

  • Allocetra: An off-the-shelf cell therapy aimed at reprogramming immune cells to restore homeostasis in severe conditions like sepsis and cytokine storm. Market share data is not publicly available due to its clinical stage status. Competitors in treating sepsis and cytokine storm include companies developing monoclonal antibodies and other immunomodulatory therapies, such as Cytokinetics (CYTK) and InflaRx (IFRX).

Market Dynamics

industry overview logo Industry Overview

The immunotherapy market is rapidly growing, driven by advancements in cell therapy and gene editing. There is a significant unmet need for effective treatments for sepsis and cytokine storm.

Positioning

Enlivex is positioned as an innovator in cell therapy, focusing on restoring immune homeostasis rather than suppressing the immune system. This approach differentiates it from many competitors.

Total Addressable Market (TAM)

The TAM for sepsis and cytokine storm treatments is estimated to be in the billions of dollars. Enlivex aims to capture a significant share of this market with Allocetra, if approved. Estimates vary significantly based on the success of clinical trials and market penetration.

Upturn SWOT Analysis

Strengths

  • Novel approach to immune modulation
  • Potential for broad application in various inflammatory conditions
  • Experienced management team
  • Positive initial clinical trial results

Weaknesses

  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on a single product candidate (Allocetra)
  • Regulatory hurdles and potential delays in approval
  • Manufacturing complexities associated with cell therapies

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications
  • Securing regulatory approvals in key markets
  • Advancements in manufacturing technologies

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Changes in regulatory landscape
  • Economic downturn affecting investment in biotechnology

Competitors and Market Share

competitor logo Key Competitors

  • Cytokinetics (CYTK)
  • InflaRx (IFRX)
  • Numerous companies developing therapies for sepsis and cytokine storm

Competitive Landscape

Enlivex's competitive advantage lies in its novel approach to immune modulation. However, it faces challenges from larger companies with more resources and established market presence.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by progress in clinical trials and expansion of the company's intellectual property portfolio.

Future Projections: Future growth is contingent on successful clinical trials and regulatory approvals for Allocetra. Analyst estimates vary widely due to the inherent risks in drug development.

Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials and exploring potential partnerships.

Summary

Enlivex Therapeutics is a clinical-stage company with a novel approach to immune modulation through its Allocetra therapy. Its strengths lie in its unique technology and positive initial trial results, but it faces challenges related to funding, regulatory hurdles, and competition. Successful clinical trials and strategic partnerships are crucial for future growth. The company's success relies heavily on the clinical development and regulatory approval of Allocetra.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Analyst Reports
  • Press Releases

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Enlivex Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 1995-12-12
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.